Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-CoV-2
infection is crucial for understanding immune protection and identifying targets for …

Importance Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients
with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate …

Background The level of evidence for HIV transmission risk through condomless sex in
serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral …

BACKGROUND & AIMS: Hepatitis C virus (HCV) induces chronic infection in 50% to 80% of
infected persons; approximately 50% of these do not respond to therapy. We performed a …

… Enos Bernasconi , Enos Bernasconi … Barbara Hasse, Bruno Ledergerber, Hansjakob Furrer,
Manuel Battegay, Bernhard Hirschel, Matthias Cavassini, Barbara Bertisch, Enos Bernasconi…

ContextAcquired immunodeficiency syndrome–related opportunistic illnesses (OIs)
continue to occur after initiation of potent antiretroviral therapy in patients with human …

Background and Aim: Decisions on public health issues are dependent on reliable
epidemiological data. A comprehensive review of the literature was used to gather country‐specific …

Background Highly active antiretroviral therapy (HAART) for human immunodeficiency virus
(HIV)-1 infection allows recovery of CD4 T lymphocytes. Few studies have explored the long-…

Background Data on adverse events to antiretroviral treatment have been recorded in
clinical trials, post-marketing analyses, and anecdotal reports. Such data might not be an up-to-…

Background . The CD4 T cell count recovery in human immunodeficiency virus type 1 (HIV-1)—infected
individuals receiving potent antiretroviral therapy (ART) shows high variability. …